A Community Bio-Tech Lab Offers a Crash Course in Designing Life — Open to the Public
By Adam Wernick,
PRI
| 06. 05. 2015
Untitled Document
“Scientists in general are awful at communicating their work to the general public,” says Jorgensen, the director of Genspace. “The consumer is already using genetically modified and genetically engineered products in their daily life. So, wouldn't it be nice if the end user were also someone who could have a say about what this technology was used for?“
Genspace, which opened in downtown Brooklyn in 2009, is the world's first community bio-lab. It offers a three-class crash course in synthetic biology to anyone who is interested. It also has a working lab space where the general public is invited to come in and learn how to do genetic science — hands on.
At Genspace, Wetherell experimented with her own DNA. Here her DNA is suspended in an agarose gel that is charged by an electical current that separates the proteins
Credit: Julia Wetherell
For $100 a month, Genspace members have access to the standardized gene sets that are the building blocks of synthetic biology. If that sounds daunting, consider this: Non-scientists make up a big part of...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Kiana Jackson and Shannon Stubblefield, New Disabled South | 02.09.2026
"MC0_8230" via Wikimedia Commons licensed under CC by 2.0
This report documents a deliberate assault on disabled people in the United States. Not an accident. Not a series of bureaucratic missteps. An assault that has been coordinated across agencies...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...